Page last updated: 2024-11-13

mk-7655

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

relebactam: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44129647
CHEMBL ID3112741
SCHEMBL ID3721178
MeSH IDM0569230

Synonyms (38)

Synonym
mk-7655
sulfuric acid mono-[7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo[3.2.1]oct-6-yl] ester
relebactam
CHEMBL3112741 ,
bdbm50447651
sulfuric acid mono-((2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) ester
relebactam [inn]
relebactam [mi]
1OQF7TT3PF ,
1174018-99-5
relebactam anhydrous
(-)-relebactam anhydrous
relebactam [who-dd]
unii-1oqf7tt3pf
SCHEMBL3721178
us8487073, 1a
bdbm1858
SMOBCLHAZXOKDQ-ZJUUUORDSA-N
(2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
sulfuric acid, mono[(1r,2s,5r)-7-oxo-2-[(4-piperidinylamino)carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl] ester
CS-5391
HY-16752
J-690043
EX-A864
AKOS027338697
mfcd28502833
DB12377
mk-7655a
(1r,2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate
AS-35205
[(2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
gtpl10852
Q27252695
S0074
BR163749
EN300-24746534
[(2s,5r)-7-oxo-2-[(piperidin-4-yl)carbamoyl]-1,6-diazabicyclo[3.2.1]octan-6-yl]oxidanesulfonic acid
AC-36163

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"0% of patients, respectively, had treatment-emergent adverse events."( Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Akers, W; Brown, ML; Du, J; Kartsonis, NA; Lee, YC; Mariyanovski, V; McLeroth, P; Paschke, A; Pedley, A; Sims, M, 2017
)
0.46
" Serious adverse events (AEs) occurred in 10% of imipenem/relebactam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no drug-related deaths), and treatment-emergent nephrotoxicity in 10% and 56% (P = ."( RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Aggrey, A; Boucher, HW; Brown, ML; Butterton, JR; Du, J; File, TM; Joeng, HK; Kartsonis, NA; Kaye, KS; Khan, I; Köksal, I; Lyulko, O; Motsch, J; Murta de Oliveira, C; Paschke, A; Stus, V; Tipping, RW; Young, K, 2020
)
0.56
" Serious adverse events (AEs) occurred in 26."( A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Boucher, HW; Brown, ML; Butterton, JR; Chen, LF; David-Wang, A; Du, J; Kartsonis, NA; Kaye, KS; Losada, MC; Paschke, A; Patel, M; Rizk, ML; Rodríguez Gonzalez, D; Roquilly, A; Tipping, R; Titov, I; Wunderink, RG; Young, K, 2021
)
0.62
" Adverse events (AEs) were reported in 74."( The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
Aoyama, N; Bando, H; Brown, M; Kawahara, K; Kikukawa, H; Kohno, S; Paschke, A; Shirakawa, M; Takase, A; Yoneyama, F, 2021
)
0.62
" Relebactam/imipenem/cilastatin was well tolerated; mild adverse events occurred during single dosing, and one participant experienced serious adverse events after multiple doses."( A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
Boundy, KE; Colon-Gonzalez, F; Li, H; Liu, N; Patel, M; Wang, H; Wang, X; Wei, Y; Yan, B; Zang, Y; Zhang, S; Zhao, X, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
"This phase I study assessed the intrapulmonary pharmacokinetic profiles of relebactam (MK-7655), a novel β-lactamase inhibitor, and imipenem."( Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Bi, S; Butterton, JR; Chavez-Eng, CM; Gotfried, MH; Jumes, PA; Mangin, E; Rhee, EG; Rizk, ML; Zhang, Z; Zhao, T, 2018
)
0.7
"Simulations demonstrated that the ratio of the area under the concentration-time curve for free drug to the minimum inhibitory concentration (fAUC/MIC) was the pharmacokinetic driver for relebactam, with a target fAUC/MIC=7."( A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
Bhagunde, P; Carr, D; Racine, F; Rizk, ML; Wu, J; Young, K; Zhang, Z, 2019
)
0.51
" This decision was based on substantial clinical and pre-clinical data, including rigorous pharmacokinetic and pharmacodynamic work, and is an important step forward in the management of these debilitating conditions."( Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy.
McCarthy, MW, 2020
)
0.56
" Population pharmacokinetic models with and without covariates were fit using the non-parametric adaptive grid algorithm in Pmetrics."( Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
Fratoni, AJ; Kuti, JL; Mah, JW; Nicolau, DP, 2022
)
0.72
" A base population pharmacokinetic model with two-compartments fitted the data best."( Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
Fratoni, AJ; Kuti, JL; Mah, JW; Nicolau, DP, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"β-Lactamase inhibitors with a bicyclic urea core and a variety of heterocyclic side chains were prepared and evaluated as potential partners for combination with imipenem to overcome class A and C β-lactamase mediated antibiotic resistance."( Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
Blizzard, TA; Bodner, R; Chen, H; Fitzgerald, P; Gude, C; Ha, S; Hairston, N; Hammond, ML; Hermes, J; Imbriglio, J; Kim, S; Lu, J; Ogawa, A; Painter, RE; Park, YW; Raghoobar, S; Scapin, G; Sharma, N; Wisniewski, D; Wu, J; Young, K, 2014
)
0.77
"Imipenem/relebactam is a carbapenem/β-lactamase inhibitor combination with in vitro activity against Pseudomonas aeruginosa and Enterobacterales, including KPC producers."( In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model.
Abdelraouf, K; Nicolau, DP; Reyes, S, 2020
)
0.56
" The aim of this study was to evaluate the in vitro efficacy of aztreonam (ATM) in combination with CAZ/AVI, M/V, and I/R against 40 MDR, MBL-producing, and serine-β-lactamases co-producing Klebsiella pneumoniae using the Etest method."( Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
Kasimati, A; Magkafouraki, E; Maraki, S; Mavromanolaki, VE; Moraitis, P; Scoulica, E; Stafylaki, D, 2021
)
0.62
"The aim of this study was to investigate in vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant Gram-negative pathogens."( In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens.
Chen, L; Chen, T; Fang, R; Liao, W; Xu, C; Zhang, S; Zhou, C; Zhou, T, 2022
)
0.72
" In this study, we analyzed the in vitro activity of those novel antibacterial agents alone or in combination with polymyxin B against the CR-A."( In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" However, there are few guidelines for the optimal dosing of inhibitors."( Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.
Bhagunde, P; Chang, KT; Hirsch, EB; Ledesma, KR; Nikolaou, M; Tam, VH, 2012
)
0.38
" Mathematical model assessments were evaluated experimentally using clinically relevant dosing regimens of imipenem, with or without MK-7655, in a hollow-fiber infection model (HFIM)."( In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.
Chang, KT; Hirsch, EB; Ledesma, KR; Motyl, MR; Schwartz, MS; Tam, VH, 2012
)
0.9
" Our discussion includes the importance of selecting the appropriate partner β-lactam and dosing regimens for these promising agents."( New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.
Bonomo, RA; Drawz, SM; Papp-Wallace, KM, 2014
)
0.4
"We assessed the antibacterial effect of human simulations of dosing with imipenem/relebactam (with or without amikacin) on Enterobacteriaceae or Pseudomonas aeruginosa over 7 or 14 day antibiotic exposures."( Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures.
Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2019
)
0.51
" These dosing regimens provide sufficient antibacterial coverage (MIC ≤ 4 μg/mL) for all renal groups."( Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections.
Bhagunde, P; Copalu, W; Kulkarni, P; Lala, M; Patel, P; Rizk, ML; Watson, K; Xu, M; Young, K, 2019
)
0.51
" Study PN019 evaluated the PK of REL (250 mg) and imipenem (500 mg; dosed as IMI) with/without probenecid (1 g; OAT inhibitor) in healthy adults."( Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.
Bhagunde, P; Boundy, K; Butterton, JR; Colon-Gonzalez, F; Garrett, G; Jumes, P; Lala, M; Lasseter, K; Liu, Y; Marbury, T; Rhee, EG; Rizk, ML; Wu, J; Xu, SS, 2020
)
0.56
" Available clinical and pharmacokinetic data support the approved dosage of a 30-minute infusion of imipenem 500 mg-cilastatin 500 mg-relebactam 250 mg every 6 hours, along with dosage adjustments based on renal function."( Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Claeys, KC; Rybak, JM; Smith, JR, 2020
)
0.56
"This phase 3, multicenter, open-label, noncomparative study (NCT03293485) evaluated relebactam/imipenem/cilastatin (250 mg/500 mg/500 mg) dosed every 6 h for 5-14 days in Japanese patients with complicated intra-abdominal infections (cIAIs) or complicated urinary tract infections (cUTIs), including those with secondary sepsis."( The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
Aoyama, N; Bando, H; Brown, M; Kawahara, K; Kikukawa, H; Kohno, S; Paschke, A; Shirakawa, M; Takase, A; Yoneyama, F, 2021
)
0.62
" At the recommended IMI/REL dosing regimens across renal categories, greater than 90% of patients in all renal function groups were predicted to achieve joint pharmacokinetic/pharmacodynamic targets at a minimum inhibitory concentration breakpoint of ≤2 μg/ml, regardless of ventilation status."( Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia.
Bellanti, F; Copalu, W; Daryani, NM; Gheyas, F; Hilbert, DW; Kulkarni, P; Noormohamed, N; Patel, M; Rizk, ML; Young, K, 2022
)
0.72
" IMI/REL is a therapeutic option in HAP and VAP at approved dosage imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg once every 6h, by an IV infusion over 30 min."( New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
Alarcón, T; Girón, RM; Gómez-Punter, RM; Ibáñez, A, 2022
)
0.72
"Despite enhanced clearance of both imipenem and relebactam, the currently approved dosing regimen for normal renal function was predicted to achieve optimal exposure in critically-ill patients with ARC sufficient to treat most susceptible pathogens."( Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
Fratoni, AJ; Kuti, JL; Mah, JW; Nicolau, DP, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1561473Inhibition of CTX-M2 in beta-lactam-resistant Escherichia coli TG1 transfected with pBGS18 plasmid encoding replication origin and kanamycin resistance assessed as potentiation of ampicillin-induced antibacterial activity by measuring fold reduction in am
AID1529367Inhibition of beta lactamase KPC in Klebsiella pneumoniae clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC90 at 4 ug/ml (Rvb = 16 ug/ml)2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1561466Inhibition of TEM-1 in penicillin-resistant Escherichia coli TG1 transfected with pBGS18 plasmid encoding replication origin and kanamycin resistance assessed as potentiation of ampicillin-induced antibacterial activity by measuring ampicillin MIC at 16 u
AID1677283Potentiation of imipenem-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 86052 clinical isolate assessed as fold reduction in imipenem MIC at 8 uM2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1695048Irreversible inhibition of beta lactamase KPC-2 in Klebsiella pneumoniae assessed as off-rate constant using nitrocefin as substrate preincubated for 30 mins followed by substrate addition2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition.
AID1529366Inhibition of ESBL in Pseudomonas aeruginosa clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC at 4 ug/ml2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1529411Inhibition of beta lactamase KPC in Klebsiella pneumoniae clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC50 at 4 ug/ml (Rvb >16 ug/ml)2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1677279Potentiation of imipenem-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 109084 clinical isolate assessed as fold reduction in imipenem MIC at 8 uM2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1529363Inhibition of ESBL in Escherichia coli clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC at 4 ug/ml2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1529368Inhibition of beta lactamase KPC in imipenem-resistant Pseudomonas aeruginosa clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC90 at 4 ug/ml (Rvb = 8 ug/ml)2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1529364Inhibition of ESBL in Klebsiella pneumoniae clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC at 4 ug/ml2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1561468Inhibition of CMY-2 in beta-lactam-resistant Escherichia coli TG1 transfected with pBGS18 plasmid encoding replication origin and kanamycin resistance assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC at 1
AID1561469Inhibition of DHA-1 in beta-lactam-resistant Escherichia coli TG1 transfected with pBGS18 plasmid encoding replication origin and kanamycin resistance assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC at 1
AID1695046Inhibition of beta lactamase KPC-2 in Klebsiella pneumoniae assessed as apparent inhibition constant using nitrocefin as substrate measured without preincubation by Dixon plot analysis2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition.
AID1677280Potentiation of imipenem-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 108590 clinical isolate assessed as fold reduction in imipenem MIC at 8 uM2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1561463Inhibition of OXA-23 in carbapenem-resistant Acinetobacter baumannii ATCC 17978 transfected with pET-RA-KmR plasmid encoding rifampicin and kanamycin resistance assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC
AID1529365Inhibition of ESBL in Enterobacter sp. clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC at 4 ug/ml2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1069403Inhibition of beta-lactamase Oxa40 in Acinetobacter baumannii assessed as inhibition of hydrolysis of nitrocefin2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
AID1561467Inhibition of CTX-M2 in beta-lactam-resistant Escherichia coli TG1 transfected with pBGS18 plasmid encoding replication origin and kanamycin resistance assessed as potentiation of ampicillin-induced antibacterial activity by measuring ampicillin MIC at 16
AID1529412Inhibition of beta lactamase KPC in imipenem-resistant Pseudomonas aeruginosa clinical isolate assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC50 at 4 ug/ml (Rvb >16 ug/ml)2018MedChemComm, Sep-01, Volume: 9, Issue:9
β-lactam/β-lactamase inhibitor combinations: an update.
AID1069401Inhibition of beta-lactamase in Pseudomonas aeruginosa CL 5701 assessed as drug concentration required to reduce imipenem MIC to 4 ug/ml2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
AID1677281Potentiation of imipenem-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 107092 clinical isolate assessed as fold reduction in imipenem MIC at 8 uM2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1069404Inhibition of beta-lactamase AmpC in Acinetobacter baumannii assessed as inhibition of hydrolysis of nitrocefin2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
AID1069405Inhibition of beta-lactamase AmpC in Pseudomonas aeruginosa assessed as inhibition of hydrolysis of nitrocefin2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
AID1069406Inhibition of beta-lactamase KPC-2 in Klebsiella pneumoniae assessed as inhibition of hydrolysis of nitrocefin2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
AID1069400Inhibition of beta-lactamase in Acinetobacter baumannii CL 6188 assessed as drug concentration required to reduce imipenem MIC to 4 ug/ml2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
AID1561464Inhibition of OXA-24/40 in carbapenem-resistant Acinetobacter baumannii ATCC 17978 transfected with pET-RA-KmR plasmid encoding rifampicin and kanamycin resistance assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem M
AID1069402Inhibition of beta-lactamase in Klebsiella pneumoniae CL 6569 assessed as drug concentration required to reduce imipenem MIC to 4 ug/ml2014Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.
AID1677282Potentiation of imipenem-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 88949 clinical isolate assessed as fold reduction in imipenem MIC at 8 uM2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1561465Inhibition of OXA-48 in beta-lactam-resistant Klebsiella pneumoniae assessed as potentiation of imipenem-induced antibacterial activity by measuring imipenem MIC at 16 ug/mL in Mueller-Hinton broth by CLSI protocol based method (Rvb = 64 ug/mL)
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (137)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's41 (29.93)24.3611
2020's96 (70.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.17 (24.57)
Research Supply Index5.01 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (6.43%)5.53%
Reviews13 (9.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other118 (84.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]